News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Genetown
Abiomed Reports Updated USpella Results at TCT 2010
September 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced updated clinical data from USpella, a U.S. multicenter, observational registry of Impella 2.5® patients.
Twitter
LinkedIn
Facebook
Email
Print
Events
MORE ON THIS TOPIC
Cardiovascular disease
Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial
November 10, 2025
·
4 min read
·
Heather McKenzie
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
October 29, 2025
·
3 min read
·
Heather McKenzie
Cell and Gene Therapy
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy
October 6, 2025
·
5 min read
·
Ben Hargreaves
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
October 6, 2025
·
5 min read
·
Ben Hargreaves
